CD13 Antibody (A-5): sc-166270

CD13 Antibody (A-5) is a mouse monoclonal IgG2a antibody that detects CD13 in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). CD13, also known as aminopeptidase N, is a type II transmembrane glycoprotein predominantly expressed on myeloid cells such as monocytes, basophils, eosinophils, and neutrophils, as well as in certain epithelial cells, fibroblasts, and osteoclasts. CD13 functions as a zinc-binding metalloprotease, playing a crucial role in the digestion of peptides and the inactivation of regulatory peptides like enkephalins, which are important for pain modulation and stress response. CD13 expression is particularly significant in cancer, as CD13 has been implicated in enhancing the invasive capacity and metastatic behavior of cancer cells. Inhibiting CD13 activity can lead to apoptosis in CD13-positive cancer cells, making CD13 a potential target for therapeutic intervention. Furthermore, basic fibroblast growth factor (bFGF) expression has been shown to upregulate CD13 in human melanoma cells, highlighting the regulatory mechanisms that influence CD13 expression and the potential implications for tumor progression. Anti-CD13 antibody (A-5) is an essential tool for researchers investigating CD13 roles in both normal physiology and pathological conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD13 Antibody (A-5) References:

1. CD13/aminopeptidase N in collagen vascular diseases.  |  Dan, H., et al. 2003. Rheumatol Int. 23: 271-6. PMID: 13680152
2. CD13/APN regulates endothelial invasion and filopodia formation.  |  Petrovic, N., et al. 2007. Blood. 110: 142-50. PMID: 17363739
3. The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas.  |  Bovio, IM. and Allan, RW. 2008. Am J Clin Pathol. 130: 628-34. PMID: 18794057
4. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.  |  Zhang, Z., et al. 2015. Tumour Biol. 36: 8167-75. PMID: 25990455
5. Macrophage Polarization Modulates FcγR- and CD13-Mediated Phagocytosis and Reactive Oxygen Species Production, Independently of Receptor Membrane Expression.  |  Mendoza-Coronel, E. and Ortega, E. 2017. Front Immunol. 8: 303. PMID: 28396660
6. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.  |  Raimbault, A., et al. 2019. Br J Haematol. 184: 625-633. PMID: 30198568
7. Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells.  |  Ji, S., et al. 2021. Front Pharmacol. 12: 660377. PMID: 34045966
8. Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2.  |  Ruan, Z., et al. 2023. Open Life Sci. 18: 20220637. PMID: 37426619
9. Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.  |  Zhang, J., et al. 2023. Molecules. 28: PMID: 37687169
10. An engineered A549 cell line expressing CD13 and TMPRSS2 is permissive to clinical isolate of human coronavirus 229E.  |  Lie, LK., et al. 2023. Virology. 588: 109889. PMID: 37778059

The preferred CD13 antibody is CD13 Antibody (3D8): sc-13536.